SunWay Biotech Co (ROCO:1271) Ending Cash Position: NT$726 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:1271 SunWay Biotech Co Ltd ROCO:1271
82 GF Score
Price NT$59.70
GF Value NT$113.22
Valuation Significantly Undervalued
! 8 Warning Signs
View Full Analysis

What is SunWay Biotech Co Ending Cash Position?

SunWay Biotech Co ROCO:1271 -0.17% 82 Ending Cash Position is NT$726 Mil as of Jun. 2026. GuruFocus rates ROCO:1271 with a GF Score™ of 82/100 and a GF Value™ of NT$113.22 (Significantly Undervalued). The stock has 8 warning signs investors should review.

SunWay Biotech Co's Ending Cash Position for the quarter that ended in Jun. 2026 was NT$726 Mil.

SunWay Biotech Co's quarterly Ending Cash Position declined from Jun. 2025 (NT$681 Mil) to Dec. 2025 (NT$301 Mil) but then increased from Dec. 2025 (NT$301 Mil) to Jun. 2026 (NT$726 Mil).

SunWay Biotech Co's annual Ending Cash Position declined from Dec. 2023 (NT$362 Mil) to Dec. 2024 (NT$294 Mil) but then increased from Dec. 2024 (NT$294 Mil) to Dec. 2025 (NT$301 Mil).

SunWay Biotech Co Ending Cash Position Related Terms

SunWay Biotech Co Ending Cash Position Historical Data

* Premium members only.

The historical data trend for SunWay Biotech Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SunWay Biotech Co Ending Cash Position Chart

SunWay Biotech Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 346.44 123.57 362.19 293.71 301.02

SunWay Biotech Co Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 312.16 293.71 680.88 301.02 726.41
ROCO:1271
82GF Score
SunWay Biotech Co Ltd ROCO:1271
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SunWay Biotech Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

SunWay Biotech Co's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=293.705+7.3169999999999
=301

SunWay Biotech Co's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=301.022+425.391
=726

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of NT$726 Mil mean?
SunWay Biotech Co (ROCO:1271) has a Ending Cash Position of NT$726 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on SunWay Biotech Co and its competitors.
Is SunWay Biotech Co's Ending Cash Position too high?
SunWay Biotech Co's current Ending Cash Position is NT$726 Mil. Overall, SunWay Biotech Co has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SunWay Biotech Co's Ending Cash Position compare to KHC and GIS?
SunWay Biotech Co's Ending Cash Position of NT$726 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Consumer Packaged Goods company?
A good Ending Cash Position depends on the Consumer Packaged Goods industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on SunWay Biotech Co and its competitors. SunWay Biotech Co's current Ending Cash Position is NT$726 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SunWay Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, SunWay Biotech Co (ROCO:1271) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$113.22, compared to a current price of NT$59.70 — trading 47.3% below its estimated fair value. The current Ending Cash Position is NT$726 Mil. SunWay Biotech Co's overall GF Score™ is 82/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For SunWay Biotech Co (ROCO:1271), the current Ending Cash Position is NT$726 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SunWay Biotech Co (ROCO:1271) Overvalued in 2026?

Based on GuruFocus' analysis, SunWay Biotech Co stock appears to be undervalued. The current stock price of NT$59.70 is trading 47.3% below its estimated GF Value™ of NT$113.22. GuruFocus considers SunWay Biotech Co to be Significantly Undervalued.

Key valuation signals for ROCO:1271:

  • Ending Cash Position: NT$726 Mil
  • GF Value™: NT$113.22 vs. price of NT$59.70 (47.3% below fair value)
  • GF Score™: 82/100 with 8 warning signs

No single metric tells the full story. See the ROCO:1271 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SunWay Biotech Co Business Description

Address No. 139, Xing’ai Road, Neihu District, Taipei, TWN, 11494
SunWay Biotech Co Ltd is engaged in the research, design and manufacturing of Monascus purpureus NTU 568, Lactobacillus paracasei subsp, paracasei NTU 101, and the related products.
82GF Score

Get the complete analysis for ROCO:1271

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$59.70
Price
NT$113.22
GF Value